YU69400A - Biorazgradivi alginatni gelovi sa kontinualnim oslobađanjem - Google Patents

Biorazgradivi alginatni gelovi sa kontinualnim oslobađanjem

Info

Publication number
YU69400A
YU69400A YU69400A YU69400A YU69400A YU 69400 A YU69400 A YU 69400A YU 69400 A YU69400 A YU 69400A YU 69400 A YU69400 A YU 69400A YU 69400 A YU69400 A YU 69400A
Authority
YU
Yugoslavia
Prior art keywords
alginate gels
biodegradable sustained
release alginate
release
sustained
Prior art date
Application number
YU69400A
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of YU69400A publication Critical patent/YU69400A/sh
Publication of RS49841B publication Critical patent/RS49841B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na formulacije sa kontinualnim oslobadjanjem koje koriste biorazgradive alginatne gelove ili čestice biorazgradivog alginata, i na postupke njihovog dobijanja.[The present invention relates to sustained-release formulations using biodegradable alginate delayed gels or particles and methods thereof.
YUP-694/00A 1998-05-18 1999-05-14 Biorazgradivi alginatni gelovi sa kontinualnim oslobađanjem RS49841B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/080,832 US6432449B1 (en) 1998-05-18 1998-05-18 Biodegradable sustained-release alginate gels

Publications (2)

Publication Number Publication Date
YU69400A true YU69400A (sh) 2003-02-28
RS49841B RS49841B (sr) 2008-08-07

Family

ID=22159900

Country Status (25)

Country Link
US (2) US6432449B1 (sh)
EP (1) EP1079811B1 (sh)
JP (1) JP2002515419A (sh)
KR (1) KR20010025023A (sh)
CN (1) CN1309556A (sh)
AT (1) ATE343378T1 (sh)
AU (1) AU3993999A (sh)
BG (1) BG65397B1 (sh)
BR (1) BR9910553A (sh)
CA (1) CA2331446C (sh)
CY (1) CY1105944T1 (sh)
DE (1) DE69933763T2 (sh)
DK (1) DK1079811T3 (sh)
EA (1) EA003670B1 (sh)
ES (1) ES2275341T3 (sh)
HU (1) HUP0101895A3 (sh)
IL (1) IL139617A0 (sh)
NO (1) NO20005564L (sh)
NZ (1) NZ507943A (sh)
PL (1) PL199499B1 (sh)
PT (1) PT1079811E (sh)
RS (1) RS49841B (sh)
SK (1) SK16752000A3 (sh)
WO (1) WO1999059549A1 (sh)
ZA (1) ZA200006299B (sh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
WO2002100425A1 (en) * 2001-06-11 2002-12-19 Ltt Institute Co., Ltd. Aggregate composition for sustained-release preparation, process for producing the same, and sustained-release preparation containing the same
WO2003062199A2 (en) * 2002-01-16 2003-07-31 Agency For Disease Diagnosis And Prevention Pace-a microspheres for delivery of antigens
US6592852B1 (en) * 2002-04-25 2003-07-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Zinc citrate beads in oral compositions
KR100523953B1 (ko) * 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
KR100507545B1 (ko) * 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP4459543B2 (ja) * 2003-03-17 2010-04-28 株式会社メドジェル 徐放性ハイドロゲル製剤
CA2544432C (en) * 2003-11-04 2011-06-28 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
BRPI0515973B8 (pt) 2004-10-12 2021-07-27 Fmc Biopolymer As kit para produzir um gel de alginato, composição para preparar um gel e uso
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US8663686B2 (en) * 2005-05-09 2014-03-04 University Of Washington Biodegradable chitosan-PEG compositions and methods of use
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
CN101557801B (zh) * 2006-07-14 2013-10-30 Fmc生物聚合物联合股份有限公司 含有低分子量藻酸盐的水凝胶和从其制备的生物构建物
DE102007039871A1 (de) * 2007-08-21 2009-02-26 Friedrich-Baur-Gmbh Weichgewebe-Implantat mit antibakterieller Wirkung
JP2010537717A (ja) * 2007-08-28 2010-12-09 エフ エム シー コーポレーション 遅効性自己ゲル化アルギネートシステムおよびその用途
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
WO2010009291A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
WO2010032242A1 (en) * 2008-09-17 2010-03-25 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELS BASED ON POLYSACCHARIDE
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
US20130149349A1 (en) * 2010-06-03 2013-06-13 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
WO2011154941A2 (en) 2010-06-07 2011-12-15 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US20130184835A1 (en) 2010-07-09 2013-07-18 Board Of Regents Of The Unversity Of Texas System Biodegradable scaffolds
SG10201701634PA (en) 2011-03-25 2017-04-27 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
CN102489027B (zh) * 2011-12-12 2014-06-04 山东凯翔生物化工有限公司 一种葡萄糖酸内酯节能浓缩方法及装置
CN103830266A (zh) * 2013-04-24 2014-06-04 杨亚勤 部分氧化海藻酸钠羧甲基化衍生物的制备方法和应用
RU2548777C2 (ru) * 2013-07-09 2015-04-20 Александр Александрович Кролевец Способ получения частиц инкапсулированных жирорастворимой полимерной оболочкой солей металлов, обладающих супрамолекулярными свойствами
WO2016010927A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
AU2015289967A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
US10835604B2 (en) * 2015-08-13 2020-11-17 Northeastern University Biomaterials for combined radiotherapy and immunotherapy of cancer
EP3501553A1 (en) * 2017-12-21 2019-06-26 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Hydrogel comprising manganese, methods and uses thereof
CN109293138A (zh) * 2018-10-08 2019-02-01 曹布道 一种养殖污水净化处理方法
US20220241193A1 (en) 2019-06-21 2022-08-04 Alfasigma S.P.A. Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients
CN112426981B (zh) * 2020-11-30 2021-12-28 西安交通大学 一种金属离子交联水凝胶及制备方法和应用
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
CN112843328B (zh) * 2021-02-25 2022-05-13 山东大学 一种具有抑菌作用的鲍鱼壳粉/ZnO复合材料掺杂的智能水凝胶伤口敷料的制备方法
CN114539442A (zh) * 2022-04-02 2022-05-27 青岛海之林生物科技开发有限公司 一种脂溶性藻酸乙酯及其制备方法与应用
CN115850533B (zh) * 2022-09-28 2023-07-21 青岛格诚经纬生物科技有限公司 一种海藻酸材料及其制备方法、应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
JPS5416979B2 (sh) * 1972-01-08 1979-06-26
US4401456A (en) * 1980-01-09 1983-08-30 The United States Of America As Represented By The Secretary Of Agriculture Controlled release of bioactive materials using alginate gel beads
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US5147861A (en) * 1986-06-30 1992-09-15 Fidia S.P.A. Esters of alginic acid
JPS645460A (en) * 1987-06-29 1989-01-10 Sanei Kagaku Kogyo Kk Production of delaying gelatinous material
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2275686B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
AU698393B2 (en) * 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
US5660859A (en) * 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
WO1997015322A1 (en) * 1995-10-25 1997-05-01 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE69838750T2 (de) * 1997-05-16 2008-10-30 Amgen Inc., Thousand Oaks Zeitverzögerte gelzusammensetzungen mit verlängerter wirkstoffverabreichung
GB2339442B (en) * 1998-07-09 2002-06-05 Smith International Downhole tension swivel sub

Also Published As

Publication number Publication date
PT1079811E (pt) 2007-01-31
IL139617A0 (en) 2002-02-10
BR9910553A (pt) 2001-01-30
US6432449B1 (en) 2002-08-13
AU3993999A (en) 1999-12-06
US20020168406A1 (en) 2002-11-14
HUP0101895A2 (hu) 2001-10-28
KR20010025023A (ko) 2001-03-26
ES2275341T3 (es) 2007-06-01
WO1999059549A1 (en) 1999-11-25
EP1079811B1 (en) 2006-10-25
ATE343378T1 (de) 2006-11-15
BG104943A (en) 2001-07-31
NZ507943A (en) 2003-08-29
CY1105944T1 (el) 2011-04-06
SK16752000A3 (sk) 2001-09-11
CA2331446A1 (en) 1999-11-25
CA2331446C (en) 2004-03-16
PL199499B1 (pl) 2008-09-30
EA003670B1 (ru) 2003-08-28
HUP0101895A3 (en) 2004-01-28
DK1079811T3 (da) 2007-02-26
JP2002515419A (ja) 2002-05-28
DE69933763T2 (de) 2007-10-04
NO20005564D0 (no) 2000-11-03
EP1079811A1 (en) 2001-03-07
NO20005564L (no) 2001-01-18
EA200001200A1 (ru) 2001-04-23
CN1309556A (zh) 2001-08-22
PL344337A1 (en) 2001-11-05
DE69933763D1 (de) 2006-12-07
ZA200006299B (en) 2001-05-30
BG65397B1 (bg) 2008-06-30
RS49841B (sr) 2008-08-07

Similar Documents

Publication Publication Date Title
ZA200006299B (en) Biodegradable sustained-release alginate gels.
ZA983089B (en) Sustained-release alginate gels
WO1998051348A3 (en) Sustained-release delayed gels
MXPA01007710A (es) Agente de secado por congelacion que contiene paramilon, su produccion y uso.
IL147803A0 (en) 28-epirapalogs
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
BG105437A (en) REFLECTIVELY MODIFIED COMPOSITIONS AND METHODS FOR OBTAINING THEM
EP1056456A4 (en) R-LANSOPRAZOL COMPOSITIONS AND TREATMENTS THEREFOR
ID23809A (id) Komposisi-komposisi alginat yang dapat dituang
AU1915399A (en) Cs-1 peptidomimetics, compositions and methods of using the same
EP1073333A4 (en) S-RABEPRAZOL COMPOSITIONS AND METHODS
EP1139981A4 (en) COMPOSITIONS AND RELATED METHODS OF USE
AU6849198A (en) Neurotrypsin
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.
AU5623599A (en) Aza-cyclodepsipeptides and their use as antiparasitics
EP1088067A4 (en) TECHNIQUES AND COMPOSITIONS FOR MODULATING SPERMATOGENESIS
EP1073332A4 (en) R-RABEPRAZOL COMPOSITIONS AND METHODS
AU3661799A (en) Horticultural compositions comprising amphoteric polymers and methods of utilizing the horticultural compositions
AU2003200609A1 (en) Biodegradable sustained-release alginate gels
AU1480801A (en) Compositions and methods for the diminution or elimination of various cancers
AU2679599A (en) Compositions and methods for modification of the gravitropic response of plants
EP1021610A4 (en) PHOTO-STABILIZING POLYMER COMPOSITIONS AND PROCESSES FOR PRODUCING THE SAME
ZA972718B (en) Compositions and methods for production of male-sterile plants.